Crisantaspase
T-Cell Acute Lymphoblastic Leukemia
University of Washingtonprotein_peptidePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 73/ 100
Competitive context
75 Active assets in the T-Cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vincristine Sulfate Children's Oncology Group | Phase 3 | BB |
Pegaspargase Children's Oncology Group | Phase 3 | BB |
Daunomycin SWOG Cancer Research Network | Phase 3 | BB |
Mercaptopurine Anhydrous SWOG Cancer Research Network | Phase 3 | BB |
Cytarabine SWOG Cancer Research Network | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Crisantaspase is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →